

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1-16. (Cancelled).

17. (Currently Amended) A method for delivering an extraneous substance ~~drug~~ via blood-brain barrier into a patient's brain ~~by a cell line of microglia~~, the method comprising the step of administering to the patient microglia cells comprising a drug, wherein the microglia cells are selected from biologically pure cell lines of microglia that have identifying characteristics of cell line Ra2 (FERM BP-7061) or cell line GMI-R1 (FERM BP-7062) and which said cell line of microglia may pass through a blood-brain barrier ~~wherein the extraneous substance is a drug~~.

18-20. (Cancelled).

21. (Currently Amended) The method according to ~~claim 17~~ — claim 17, wherein the cell line of microglia is originated from new born mouse.

22. (Previously Presented) The method according to claim 21, wherein the cell line of microglia is a biologically pure cell line of microglia having identifying characteristics of the cell line Ra2 (FERM BP-7061) which passes through blood-brain barrier.

23. (Currently Amended) The method according to ~~claim 17~~ — claim 17, wherein the cell line of microglia is originated from new born rat.

24. (Previously Presented) The method according to claim 23, wherein the cell line of microglia is a biologically pure cell line of microglia having

Application No. 10/602,234
Amendment dated October 24, 2005
Reply to Office Action of June 24, 2005

Docket No.: 48781DIV(71526)

identifying characteristics of the cell line GMI-R1 (FERM BP-7062) which passes through blood-brain barrier.